Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTOXIN vs BOTOX for Glabellar Lines
NCT04996810Phase 2Completed
- Sponsor
- Sophiris Bio Inc.
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PROTOXIN in glabellar lines (2 arms), sponsored by Sophiris Bio Inc. Primary endpoints: Number of subjects with treatment-related adverse events at 12 weeks and Glabellar line improvement rate confirmed with investigator's assessment at 4 weeks. Started Dec 2020; status: completed.
02
Drugs
PROTOXIN
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT04996810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996810.